Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

April 30, 1998

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Lung Cancer
Interventions
DRUG

paclitaxel

DRUG

topotecan hydrochloride

RADIATION

radiation therapy

Trial Locations (19)

55805

CCOP - Duluth, Duluth

55905

Mayo Clinic Cancer Center, Rochester

56303

CentraCare Health Plaza, Saint Cloud

57104

CCOP - Sioux Community Cancer Consortium, Sioux Falls

57709

Rapid City Regional Hospital, Rapid City

58201

Altru Health Systems, Grand Forks

58501

Medcenter One Health System, Bismarck

61602

CCOP - Illinois Oncology Research Association, Peoria

61801

CCOP - Carle Cancer Center, Urbana

68131

CCOP - Missouri Valley Cancer Consortium, Omaha

70121

CCOP - Ochsner, New Orleans

85259-5404

CCOP - Scottsdale Oncology Program, Scottsdale

52403-1206

CCOP - Cedar Rapids Oncology Project, Cedar Rapids

50309-1016

CCOP - Iowa Oncology Research Association, Des Moines

51101-1733

Siouxland Hematology-Oncology, Sioux City

67214-3882

CCOP - Wichita, Wichita

43623-3456

CCOP - Toledo Community Hospital Oncology Program, Toledo

17822-2001

CCOP - Geisinger Clinic and Medical Center, Danville

S4T 7T1

Allan Blair Cancer Centre, Regina

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00003281 - Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter